Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 13 % of short-term debt in 2025; threshold 65 %.
-
Figures corrected NBB
Corrected annual account filed for 2022.
-
Busy address KBO
36 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
DeuterOncology from Liège, company number BE0754971388, closed financial year 2025 with a result of € -3.6 million after tax. For that financial year DeuterOncology recorded a gross margin of € -3.3 million and equity of € -2.6 million. Compared with financial year 2024, the result moved from € -2.1 million to € -3.6 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ -2.6 million
▼ € 3.6 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3.6 million
▼ 70 % more loss than in 2024
Profit after tax over the fiscal year.
€ 210,729
▼ 75% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -11.2 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 3 million
Loans from banks and other lenders, long and short.
€ 185,175
▼ 39% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,294,417 | € -1,864,132 | € -1,987,149 | € -3,279,454 | ▼ € 1.3 million |
| Profit after taxes | € -2,387,844 | € -2,029,591 | € -2,114,850 | € -3,600,784 | ▼ € 1.5 million |
| Equity | € 3,309,968 | € 1,707,402 | € 965,547 | € -2,635,237 | ▼ € 3.6 million |
| Total debts | € 293,705 | € 269,011 | € 305,623 | € 3,323,265 | ▲ € 3 million |
| Cash | € 3,550,735 | € 1,551,443 | € 829,070 | € 210,729 | ▼ 75% |
| Retained profit | € -3,488,183 | € -5,517,774 | € -7,632,624 | € -11,233,408 | ▼ € 3.6 million |
| Bank debt | € 0 | € 0 | € 0 | € 3,005,138 | |
| Balance sheet total | € 3,603,673 | € 1,976,413 | € 1,271,170 | € 688,028 | ▼ 46% |
Key figures of DeuterOncology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DeuterOncology?
What happened at DeuterOncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Newton Biocapital Partners SRL stepped down as director. NBB
- NOSHAQ PARTNERS SRL stepped down as director. NBB
- Iker Huerga stepped down as director. NBB
- Alexander Patrick Dolan stepped down as director. NBB
- Kipp Richard Fairchild Davis stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 3.6 million. Source: NBB ↗
- Iker Huerga became a director. NBB
- Alexander Patrick Dolan became a director. NBB
In short
From € 2.4 million loss in 2022 to € 3.6 million loss in 2025.
A new publication or filing at DeuterOncology? We notify you, reason included.
Follow DeuterOncologyDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Newton Biocapital I, pricaf privée de droit belge, INVESTSUD TECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
DeuterOncologyThe shares are held by Newton Biocapital I, pricaf privée de droit belge (69.6%) and INVESTSUD TECH (8.8%). It owns 100% of Octimet itself.
Directors
According to the 2025 annual accounts
Newton Biocapital Partners SRL
Director · represented by Pierre DETRIXHE
Also active at: SYNERGIA MEDICAL, Newton Biocapital I, pricaf privée de droit belge, Newton Biocapital I Investment Pool, EPICS THERAPEUTICS, NEUVASQ BIOTECHNOLOGIES, Aboleris Holdco, FLANDERSBIO
since 2021 · until 2032
Director · represented by Hélène SABATEL
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2022 · until 2032
Iker Huerga
Director
since 2026 · until 2032
Alexander Patrick Dolan
Director
since 2026 · until 2032
Kipp Richard Fairchild Davis
Director
since 2026 · until 2032
Shareholders
Participations
100%
Establishments
Establishment units
Physical locations of this company
Clos Chanmurly 13
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 36 companies are registered at this address.
All companies at this address →AASA Architectes
€ 155,212 gross margin · 2025
1Spatial Belgium
€ 2.7 million revenue · 2025
ICÔN INTERNATIONAL BENELUX
€ 201,776 gross margin · 2025
GESCOM
€ -686 gross margin · 2025
TECHNIQUES GENERALES ET INFRASTRUCTURES
€ 528,630 gross margin · 2025
+31 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0754.971.388
- VAT number
- BE 0754.971.388
- Registered office
- Clos Chanmurly 13, 4000 Liège
- Names & denominations
- DeuterOncology
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2020
- Peppol
- Active · Active since 10 Mar 2026
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied